Omalizumab
Based on 1 publication(s) in Google Scholar
Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE) with a KD of 0.393 nM. Omalizumab binds to the human FcγRIIb receptors with a KD of 6.37 uM. Omalizumab has the potential for persistent allergic asthma research. The component ratio of this product is Active ingredient : Excipients = 1:1.3-1:1.5.
For research use only. We do not sell to patients.
- Purity: 99.7%
- CAS No.: 242138-07-4
- Molecular Weight:146.46 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Omalizumab
More
Biological Activity
Human IgG1 kappa
Human
IGHE
Omalizumab (0.1, 0.5, 1.0, 2.0 μg/mL) has a direct effect on the B cells and can reduce the number of membrane IgE+ cells present in IL-4 plus anti-CD40 treated B cell cultures. Omalizumab alone has no effect on the viable cell number[3].
Omalizumab (1 μg/mL; 3, 7 days) reduces IL-6 secretion in human B cells. Omalizumab does not induce apoptosis in human B cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Immobilized IgE Protein, Human (HEK293, His, HY-P73907) can bind Omalizumab. The EC50 for this effect is 2.23 ng/mL.
Chemical Information
-
CAS No. 242138-07-4
-
Appearance Solid
-
Molecular Weight 146.46 kDa
-
SMILES
[Omalizumab]
-
Synonyms
Olizumab; rhuMab-E25; IGE25; RG-3648
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Blood Adv
Platelets upregulate tumor programmed death-ligand 1 in an epidermal growth factor receptor-dependent manner in vitro. [Abstract]2022 Oct 25;6(20):5668-5675. PMID: 35482455
Purity & Documentation
-
Data Sheet (261 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Peipei Liu, et al. An Omalizumab Biobetter Antibody With Improved Stability and Efficacy for the Treatment of Allergic Diseases. Front Immunol. 2020 Nov 27;11:596908. [Content Brief]
[2]. Seung Y Chu, et al. Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcγRIIb with Fc-engineered antibody. J Allergy Clin Immunol. 2012 Apr;129(4):1102-15. [Content Brief]
[3]. Marcia A Chan, et al. Omalizumab may decrease IgE synthesis by targeting membrane IgE+ human B cells. Clin Transl Allergy. 2013 Sep 2;3(1):29. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz